BREYANZI is a CD19-directed genetically modified autologous cellular immunotherapy administered as a defined composition to reduce variability in CD8-positive and CD4-positive T cell dose.

BREYANZI also includes a nonfunctional truncated epidermal growth factor receptor (EGFRt) that is co-expressed on the cell surface with the CD19-specific CAR.

CAR binding to CD19 expressed on the cell surface of tumour and normal B cells induces activation and proliferation of CAR T cells, release of pro-inflammatory cytokines, and cytotoxic killing of target cells.


* Clinical significance is unknown.